Effect of uremic serum and uremic toxins on drug metabolism in human microsomes

Regulatory Toxicology and Pharmacology

Volumn 68, Issue 2, 2014, Pages 297-303

  Volpe, Donna A ^a   Tobin, Grainne A ^a   Tavakkoli, Fatemeh ^b   Dowling, Thomas C ^b   Light, Paul D ^c   Parker, Robert J ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic renal failure; Metabolism; Uremic serum; Uremic toxins

Indexed keywords

CHRONIC RENAL FAILURE; METABOLISM; UREMIC SERUM; UREMIC TOXINS;

ADULT; ARYL HYDROCARBON HYDROXYLASES; BUPROPION; CYTOCHROME P-450 CYP3A; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MICROSOMES, LIVER; MIDDLE AGED; RENAL DIALYSIS; TESTOSTERONE; TOXINS, BIOLOGICAL; UREMIA;

EID: 84893720270     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2013.10.006     Document Type: Article

References (37)

1. Brunet P., Dou L., Cerini C., Berlan Y. Protein-bound uremic retention solutes. Adv. Renal Replace. Ther. 2003, 10:310-320.
2. Calaf R., Cerini C., Génovésio C., Verhaeghe P., Jourde-Chiche N., Bergé-Lefranc D., Gondouin B., Dou L., Morange S., Argilés A., Rathelot P., Dignat-George F., Brunet P., Charpiot P. Determination of uremic solutes in biological fluids of chronic kidney disease patients by HPLC assay. J. Chromatogr., B. 2001, 879:2281-2286.
3. Dowling T.C., Briglia A.E., Fink J.C., Hanes D.S., Light P.D., Stackiewicz L., Karyekar C.S., Eddington N.D., Weir M.R., Henrich W.L. Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease. Clin. Pharmacol. Ther. 2003, 73:427-434.
4. De Martin S., Orlando R., Bertoli M., Pegoraro P., Palatini P. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis. Clin. Pharmacol. Ther. 2006, 80:597-606.
5. Dreisbach A.W., Lertora J.J. The effect of chronic renal failure on drug metabolism and transport. Expert Opin. Drug Metabol. Toxicol. 2008, 4:1065-1074.
6. Guévin C., Michaud J., Naud J., Leblond F.A., Pichette V. Down-regulation of hepatic cytochrome P450 in chronic renal failure: role of uremic mediators. Br. J. Pharmacol. 2002, 137:1039-1046.
7. Hanada K., Ogawa R., Son K., Sasaki T., Kikkawa A., Ichihara S., Ogata H. Effects of indoxylsulfate on the in vitro hepatic metabolism of various compounds using human liver microsomes and hepatocytes. Nephron Physiol. 2006, 103:179-186.
8. Itoh Y., Ezawa A., Kikuchi K., Tsuruta Y., Niwa T. Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production. Anal. Bioanal. Chem. 2012, 403:1841-1850.
9. Joy M.S., Frye R.F., Stubbert K., Brouwer K.R., Falk R.J., Kharasch E.D. Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases. J. Clin. Pharmacol. 2010, 50:714-720.
10. Lameire N., Vanholder R., De Smet R. Uremic toxins and peritoneal dialysis. Kidney Int. 2001, 59(Suppl. 78):S292-S297.
11. Leblond F.A., Petrucci M., Dubé P., Bernier G., Bonnardeaux A., Pichette V. Downregulation of intestinal cytochrome P450 in chronic renal failure. J. Am. Soc. Nephrol. 2002, 13:1579-1585.
12. Lesaffer G., De Smet R., Lameire N., Dhondt A., Duym P., Vanholder R. Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane. Nephrol. Dial. Transplant. 2000, 15:50-57.
13. Liabeuf S., Drüeke T.B., Massy Z.A. Protein-bound uremic toxins: new insights from clinical studies. Toxins 2011, 3:911-919.
14. Luo F.J.G., Patel K.P., Marquez I.O., Plummer N.S., Hostetter T.H., Meyer T.W. Effect of increasing dialyzer mass transfer area coefficient and dialysate flow on clearance of protein-bound solutes: a pilot crossover trial. Am. J. Kidney Dis. 2009, 53:1042-1049.
15. 1-acid glycoprotein and γ-globulins. Toxicol. Lett. 2002, 136:33-41.
16. Matzke G.R., Frye R.F. Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity. Drug Saf. 1997, 16:205-231.
17. Meert N., De Smet R., Argiles A., Cohen G., Deppisch R., Drüeke T., Massy Z., Spasovski G., Stegmayr B., Zidek W., Jankowski J., Vanholder R. Inconsistency of reported uremic toxin concentrations. Artif. Organs 2007, 31:600-611.
18. Michaud J., Dubé P., Naud J., Leblond F., Desbiens K., Bonnardeaux A., Pichette V. Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Br. J. Pharmacol. 2005, 144:1067-1077.
19. Michaud J., Nolin T.D., Naud J., Dani M., Lafrance J.P., Leblond F.A., Himmelfarb J., Pichette V. Effect of hemodialysis on cytochrome P450 functional expression. J. Pharmacol. Sci. 2008, 108:157-163.
20. Naud J., Michaud J., Leblond F.A., Lefrancois S., Bonnardeaux A., Pichette V. Effects of chronic renal failure on liver drug transporters. Drug Metab. Dispos. 2008, 36:124-128.
21. Nolin T.D., Frye R.F., Le P., Le P., Sadr H., Naud J., Leblond F.A., Pichette V., Himmelfarb J. ESRD impairs nonrenal clearance of fexofenadine but not midazolam. J. Am. Soc. Nephrol. 2009, 20:2269-2276.
22. Nolin T.D., Frye R.F., Matzke G.R. Hepatic drug metabolism and transport in patients with kidney disease. Am. J. Kidney Dis. 2003, 42:906-925.
23. Nolin T.D., Appiah K., Kendrick S.A., Le P., McMonagle E., Himmelfarb J. Hemodialysis acutely improves hepatic CYP3A4 metabolic activity. J. Am. Soc. Nephrol. 2006, 17:2363-2367.
24. Nolin T.D., Naud J., Leblond F.A., Pichette V. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin. Pharmacol. Ther. 2008, 83:898-903.
25. Rege B., Krieg R., Gao N., Sarka M.A. Down-regulation of hepatic CYP3A in chronic renal insufficiency. Pharm. Res. 2003, 20:1600-1606.
26. Roboz J., Happatos D., Holland J.F. Polyol concentrations in serum during hemodialysis. Clin. Chem. 1990, 36:2082-2086.
27. Sassa T., Matsuno H., Niwa M., Kozawa O., Takeda N., Niwa T., Kumada T., Uematsu T. Measurement of furancarboxylic acid, a candidate for uremic toxin, in human serum, hair, and sweat, and analysis of pharmacological actions in vitro. Arch. Toxicol. 2000, 73:649-654.
28. Schoots A.C., De Vries P.M.J.M., Thiemann R., Hazejager W.A., Visser S.L., Oe P.L. Biochemical and neurophysiological parameters in hemodialyzed patients with chronic renal failure. Clin. Chim. Acta 1989, 185:91-107.
29. Sun H., Huang Y., Frassetto L., Benet L.Z. Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab. Dispos. 2004, 32:1239-1246.
30. Sun H., Frassetto L., Benet L.Z. Effects of renal failure on drug metabolism and transport. Pharmacol. Ther. 2006, 109:1-11.
31. Taburet A.M., Vincent I., Perello L., Coret B., Baune B., Furlan V. Impairment of drug biotransformation in renal disease: an in vitro model. Clin. Pharmacol. Ther. 1996, 59:136.
32. Tsujimoto M., Higuchi K., Shima D., Yokota H., Furukubo T., Izumi S., Yamakawa T., Otagiri M., Hirata S., Takara K., Nishiguchi K. Inhibitory effects of uraemic toxins 3-indoxl sulfate and p-cresol on losartan metabolism in vitro. J. Pharm. Pharmacol. 2010, 62:133-138.
33. Turpeinen M., Koivuviita N., Tolonen A., Reponen P., Lundgren S., Miettunen J., Metsǎrinne K., Rane A., Pelkonen O., Laine K. Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites. Br. J. Clin. Pharmacol. 2007, 64:165-173.
34. Vanholder R., De Smet R., Glorieux G., Argilés A., Baurmeister U., Brunet P., Clark W., Cohen G., De Deyn P.P., Deppisch R., Descamps-Latscha B., Henle T., Jörres A., Lemke H.D., Massy Z.A., Passlick-Deetjen J., Rodriguez M., Stegmayr B., Stenvinkel P., Tetta C., Wanner C., Zidek W. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003, 63:1934-1943.
35. Worrall S.P., Almond M.K., Dhillon S. Pharmacokinetics of bupropion and its metabolites in haemodialysis patients who smoke. A single dose study. Nephron Clin. Pract. 2007, 97:c83-89.
36. Xu B.Q., Ishii M., Ding L.R., Fischer N.E., Inaba T. Interaction of serum proteins with CYP isoforms in human liver microsomes: inhibitory effects of human and bovine albumin, alpha-globulins, alpha-1-acid glycoproteins and gamma-globulins on CYP2C19 and CYP2D6. Life Sci. 2003, 72:1953-1962.
37. Zhang Y., Zhang L., Abraham S., Apparaju S., Wu T.C., Strong J.M., Xiao S., Atkinson A.J., Thummel K.E., Leeder J.S., Lee C., Burckart G.J., Lesko L.J., Huang S.M. Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. Clin. Pharmacol. Ther. 2009, 85:302-311.